Evaluation of Bilastine's Efficacy and Safety in Treating Chronic Idiopathic Urticaria in Iraqi Patients

Overview

Journal Med J Islam Repub Iran

Specialty General Medicine

Date 2025 Feb 19

PMID 39968464

Authors

Farah Saleh Abdul-Reda

Mohammed Ah Jabarah Al-Zobaidy

Affiliations

Soon will be listed here.

Abstract

Background: Many drugs have been found to be effective in treating chronic urticaria, and many others are under investigation. Second-generation antihistamines are the first-line treatment for this condition, as they block peripheral histamine receptors with minimal drowsiness and anticholinergic effects. Therefore, the aim of the current study was to investigate the short-term efficacy and safety of bilastine in Iraqi patients with chronic idiopathic urticaria.

Methods: This prospective study was conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq during the period from January to June 2023. A total of 100 patients, 50 males and 50 females, were enrolled in this study. All these patients were switched over to Bilastine 20 mg/day for one month. The patients were evaluated using the UAS7 scoring system before and one month after bilastine therapy. Statistical analysis was performed using the Statistical Package for Social Sciences, and a paired t-test was used to compare between means. The level of statistical significance was considered at a value < 0.05.

Results: The mean UAS7 score before Bilastine treatment was 18.91 ±7.18, which was significantly reduced ( < 0.001) to 2.38 ±0.72 after one month of treatment with bilastine. Also, before Bilastine treatments, 19 patients (19%) had mild symptoms, 24 patients (24%) had moderate symptoms, and 57 patients (57%) had severe symptoms. However, after treatment, 51 patients (51%) became symptom-free and 49 patients (49%) had well-controlled urticaria.

Conclusion: Switching over to bilastine 20mg/day resulted in significant improvement in patients with chronic idiopathic urticaria who had no/ or poor response to conventional antihistamines.

References

Yagami A, Furue M, Togawa M, Saito A, Hide M . One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2016; 44(4):375-385. PMC: 5412823. DOI: 10.1111/1346-8138.13644. View

Barzilai A, Baum A, Ben-Shoshan M, Tzanani I, Hakroush R, Coster D . Epidemiological and Clinical Characteristics of Adult and Pediatric Patients with Chronic Spontaneous Urticaria. J Clin Med. 2023; 12(23). PMC: 10706916. DOI: 10.3390/jcm12237482. View

Najafipour M, Zareizadeh M, Najafipour F . Relationship between Chronic urticaria and autoimmune thyroid disease. J Adv Pharm Technol Res. 2019; 9(4):158-161. PMC: 6302681. DOI: 10.4103/japtr.JAPTR_342_18. View

Song W, Choi M, Lee D, Kwon J, Kim G, Kim M . The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 1. Definition, Methodology and First-line Management. Allergy Asthma Immunol Res. 2020; 12(4):563-578. PMC: 7224993. DOI: 10.4168/aair.2020.12.4.563. View

Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M . Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016; 175(6):1153-1165. DOI: 10.1111/bjd.14768. View

Maheshwari A, Garg T, Chander R, Debnath E . Chronic Spontaneous Urticaria: An Etiopathogenic Study. Indian J Dermatol. 2022; 67(1):92. PMC: 9154155. DOI: 10.4103/ijd.ijd_851_21. View

Thomsen S, Pritzier E, Anderson C, Vaugelade-Baust N, Dodge R, Dahlborn A . Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol. 2017; 31(6):1048-1055. DOI: 10.1111/jdv.14210. View

Helen Katelaris C, Lima H, Marsland A, Weller K, Shah A, Waserman S . How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both. J Allergy Clin Immunol Pract. 2021; 9(6):2151-2157. DOI: 10.1016/j.jaip.2021.02.026. View

Church M, Tiongco-Recto M, Ridolo E, Novak Z . Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2019; 36(3):445-454. DOI: 10.1080/03007995.2019.1681134. View

10.

Kim Y, Park S, Han K, Lee J, Kim N, Roh J . Clinical Course of Chronic Spontaneous Urticaria in the Korean Adult Population. Allergy Asthma Immunol Res. 2017; 10(1):83-87. PMC: 5705488. DOI: 10.4168/aair.2018.10.1.83. View

11.

Togawa M, Yamaya H, Rodriguez M, Nagashima H . Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. Clin Drug Investig. 2016; 36(12):1011-1021. PMC: 5107204. DOI: 10.1007/s40261-016-0447-2. View

12.

Scaglione F . Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012; 16(14):1999-2005. View

13.

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A . The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017; 72(12):2005-2016. PMC: 5724512. DOI: 10.1111/all.13209. View

14.

Jo Y, Yoo H, Kim S, Kim Y, Kim H . Clinical characteristics and treatment response of chronic spontaneous urticaria according to age: A single-center Korean study. Asian Pac J Allergy Immunol. 2019; 40(4):374-378. DOI: 10.12932/AP-050719-0594. View

15.

Hide M, Yagami A, Togawa M, Saito A, Furue M . Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study. Allergol Int. 2016; 66(2):317-325. DOI: 10.1016/j.alit.2016.08.004. View

16.

Zuberbier T, Abdul Latiff A, Abuzakouk M, Aquilina S, Asero R, Baker D . The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021; 77(3):734-766. DOI: 10.1111/all.15090. View

17.

Wertenteil S, Strunk A, Garg A . Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019; 81(1):152-156. DOI: 10.1016/j.jaad.2019.02.064. View

18.

Podder I, Dhabal A, Chakraborty S . Efficacy and Safety of Up-dosed Second-generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review. J Clin Aesthet Dermatol. 2023; 16(3):44-50. PMC: 10027330. View

19.

Cheong W, Chan A, Chng C, Chung W, Gabriel M, Godse K . Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia. Drugs Context. 2022; 11. PMC: 8932249. DOI: 10.7573/dic.2021-12-2. View

20.

Metz M, Altrichter S, Buttgereit T, Fluhr J, Fok J, Hawro T . The Diagnostic Workup in Chronic Spontaneous Urticaria-What to Test and Why. J Allergy Clin Immunol Pract. 2021; 9(6):2274-2283. DOI: 10.1016/j.jaip.2021.03.049. View